A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Study summary

RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedRSC-1255 Dose Escalation and RSC-1255 Dose Expansion

The study team can explain what participation involves.

Who it may be forAdvanced Malignant Solid Neoplasm · RAS Mutation

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 23, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1

Interventional

Where is it offered?3 U.S. locations

Locations may change over time.

Who runs it?RasCal Therapeutics, Inc.

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: RasCal Therapeutics, Inc.
Interventions being studied: Drug: RSC-1255 Dose Escalation; Drug: RSC-1255 Dose Expansion

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

(Key Factors): 1. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:
Participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition
Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit
Malignancy has progressed on standard therapy 2. Has evaluable or measurable tumor(s) in dose-escalation by standard radiological and/or laboratory assessments as applicable to their malignancy. 3. Has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG). 4. Is age ≥ 18 years. 5. Has either tissue agnostic tumors and documented RAS mutations or with glioblastoma with or without mutation in RAS

Reasons someone may not be able to joinExclusion criteria

(Key Factors): 1. Participants receiving cancer therapy at the time of enrollment. 2. Any clinically significant disease or condition affecting a major organ system. 3. Significant cardiovascular disease or electrocardiogram (ECG) abnormalities. 4. Known Gilbert's disease. 5. Has had a previous (within 2 years) or has a current malignancy other than the target cancer. 6. Intermittent hypokalemia 7. Grade 1 or higher nausea, vomiting, diarrhea at baseline due to underlying disease

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of California, Los Angeles (UCLA) Department of Medicine - Hematology/OncologyLos Angeles, California
Sarah Cannon, SCRI Oncology Partners - Health OneDenver, Colorado
Sarah Cannon, SCRI Oncology PartnersNashville, Tennessee

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 23, 2026. Always confirm current availability with the study team.

View original record ↗